Sumitomo Dainippon Pharma

Oct. 11, 2021 (PDF/344KB)Products

Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Sep. 30, 2021 (PDF/218KB)Licensing

Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds
Sep. 14, 2021R&D

Posted Video of Frontier Business Meeting - FBO Showcase - [Webcast]
Sep. 10, 2021 (PDF/120KB)Products

Sumitomo Dainippon Pharma Announces Launch of TWYMEEG for the Treatment of Type 2 Diabetes in Japan
Sep. 10, 2021 (PDF/109KB)R&D

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis

Other Notices

Jun. 30, 2021Others

Posted Factbook 2021
Jun. 24, 2021Corporate (PDF/103KB)

Sumitomo Dainippon Pharma Announces Release of Movie on Change of Company Name
May 26, 2021Corporate

Posted Notice of Convocation of the 201th Annual Shareholders' Meeting

IR Library

Movie on Change of Company Name

Change company name from April 2022
Company Introduction Movie

Continuing to challenge ourselves to support a healthy future for people
Research and Development

Aiming to create innovative pharmaceutical products
CSR

Targeting sustainable growth
Overseas Local Subsidiaries

Leading our global expansion
Frontier Business Website

Thinking BEYOND medication